Regulus Therapeutics Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense
Gain on PPP Loan forgiveness
Stock-based compensation
Gain on reduction of lease liability
Amortization of premiums and accretion of discounts on investments, net
Other
Change in operating assets and liabilities:
Contracts and other receivables
Prepaid materials
Prepaid expenses and other assets
Accounts payable
Accrued liabilities
Accrued research and development expenses
Accrued compensation
Operating lease right-of-use assets and liabilities, net
Contract liabilities
Other liabilities

Net cash used in operating activities
Investing activities
Purchases of short-term investments
Sales and maturities of short-term investments
Purchases of property and equipment
Acquisition of intangibles
Sales of property and equipment
Net cash (used in) provided by investing activities

Financing activities
Proceeds from issuance of securities through private placement, net of issuance costs
Proceeds from issuance of common stock, net
Proceeds from borrowing under Paycheck Protection Program
Proceeds from exercise of common stock options
Payments on financing leases
Principal payments on term loan
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information
Interest paid
Income taxes paid
Supplemental disclosure of non-cash investing and financing activities
Paycheck Protection Program loan forgiveness
Unsettled sales of common stock through ATM
Non-cash acquisition of property and equipment
Purchases of property and equipment included in accrued liabilities

Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents
Restricted cash

Comments